Amgen Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Amgen Inc. (AMGN) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $1.80 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-05
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.80B.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $2.70B.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $900.00M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $2.00B.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $1.80B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $2.70B 10-Q · filed 2026-05-01 |
| 2025-09-30 | $900.00M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $2.00B 10-Q · filed 2025-08-06 |
| 2025-03-31 | $3.10B 10-Q · filed 2025-05-02 |
| 2024-09-30 | $1.20B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $2.40B 10-Q · filed 2024-08-07 |
| 2024-03-31 | $3.60B 10-Q · filed 2024-05-03 |
| 2023-09-30 | $700.00M 10-Q · filed 2023-10-31 |
| 2023-06-30 | $1.40B 10-Q · filed 2023-08-04 |
| 2023-03-31 | $2.10B 10-Q · filed 2023-04-28 |
| 2022-09-30 | $600.00M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $1.30B 10-Q · filed 2022-08-05 |
| 2022-03-31 | $1.90B 10-Q · filed 2022-04-28 |
| 2021-09-30 | $600.00M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $1.20B 10-Q · filed 2021-08-04 |
| 2021-03-31 | $1.90B 10-Q · filed 2021-04-28 |
| 2020-09-30 | $700.00M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $1.40B 10-Q · filed 2020-07-29 |
| 2020-03-31 | $2.10B 10-Q · filed 2020-05-01 |
| 2019-09-30 | $300.00M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $600.00M 10-Q · filed 2019-07-31 |
| 2019-03-31 | $1.00B 10-Q · filed 2019-05-01 |
| 2018-09-30 | $300.00M 10-Q · filed 2018-10-31 |
| 2018-06-30 | $700.00M 10-Q · filed 2018-07-27 |
| 2018-03-31 | $1.00B 10-Q · filed 2018-04-25 |
| 2017-09-30 | $300.00M 10-Q · filed 2017-10-26 |
| 2017-06-30 | $600.00M 10-Q · filed 2017-07-26 |
| 2017-03-31 | $1.00B 10-Q · filed 2017-04-27 |
| 2016-09-30 | $372.00M 10-Q · filed 2016-10-28 |
| 2016-06-30 | $700.00M 10-Q · filed 2016-07-29 |
| 2016-03-31 | $1.10B 10-Q · filed 2016-05-02 |
| 2015-09-30 | $348.00M 10-Q · filed 2015-11-02 |
| 2015-06-30 | $672.00M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $1.00B 10-Q · filed 2015-04-27 |
| 2014-09-30 | $334.00M 10-Q · filed 2014-10-29 |
| 2014-06-30 | $670.00M 10-Q · filed 2014-08-05 |
| 2014-03-31 | $951.00M 10-Q · filed 2014-04-30 |
| 2012-09-30 | $103.00M 10-Q · filed 2012-11-06 |
| 2012-06-30 | $206.00M 10-Q · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |